Literature DB >> 21282445

Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.

Glenn A Pankuch1, Gengrong Lin, Aya Kubo, Eliana S Armstrong, Peter C Appelbaum, Klaudia Kosowska-Shick.   

Abstract

ACHN-490 was tested alone and in combination with cefepime, doripenem, imipenem, or piperacillin-tazobactam in a synergy time-kill analysis against 25 Pseudomonas aeruginosa strains with different resistance phenotypes. Each combination was synergistic against most isolates at 24 h, and antagonism was not observed. Combinations of ACHN-490 with cefepime, doripenem, imipenem, or piperacillin-tazobactam yielded synergies in ≥70% and ≥80% of strains at 6 and 12 h, respectively, and in ≥68% at 24 h.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21282445      PMCID: PMC3088216          DOI: 10.1128/AAC.01390-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.

Authors:  Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

Review 2.  Treatment options for multidrug-resistant nonfermenters.

Authors:  David Felipe Briceño; John P Quinn; María Virginia Villegas
Journal:  Expert Rev Anti Infect Ther       Date:  2010-03       Impact factor: 5.091

Review 3.  Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.

Authors:  John E McGowan
Journal:  Am J Med       Date:  2006-06       Impact factor: 4.965

Review 4.  Multidrug-resistant Gram-negative bacteria: how to treat and for how long.

Authors:  Helen Giamarellou
Journal:  Int J Antimicrob Agents       Date:  2010-12-03       Impact factor: 5.283

5.  Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City.

Authors:  David Landman; Paul Kelly; Martin Bäcker; Elizabeth Babu; Neha Shah; Simona Bratu; John Quale
Journal:  J Antimicrob Chemother       Date:  2010-12-03       Impact factor: 5.790

Review 6.  Combating evolution with intelligent design: the neoglycoside ACHN-490.

Authors:  Eliana S Armstrong; George H Miller
Journal:  Curr Opin Microbiol       Date:  2010-10       Impact factor: 7.934

7.  Synthesis and spectrum of the neoglycoside ACHN-490.

Authors:  James B Aggen; Eliana S Armstrong; Adam A Goldblum; Paola Dozzo; Martin S Linsell; Micah J Gliedt; Darin J Hildebrandt; Lee Ann Feeney; Aya Kubo; Rowena D Matias; Sara Lopez; Marcela Gomez; Kenneth B Wlasichuk; Raymond Diokno; George H Miller; Heinz E Moser
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

Review 8.  Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia.

Authors:  Anna M Ferrara
Journal:  Int J Antimicrob Agents       Date:  2006-02-10       Impact factor: 5.283

  8 in total
  4 in total

1.  10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; Daniel K Benjamin; John Bradley; Robert J Guidos; Ronald N Jones; Barbara E Murray; Robert A Bonomo; David Gilbert
Journal:  Clin Infect Dis       Date:  2013-04-17       Impact factor: 9.079

2.  A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides.

Authors:  Nishad Thamban Chandrika; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2015-11-19       Impact factor: 3.597

Review 3.  Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections.

Authors:  Kristin J Labby; Sylvie Garneau-Tsodikova
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

Review 4.  Antibiotics and bacterial resistance in the 21st century.

Authors:  Richard J Fair; Yitzhak Tor
Journal:  Perspect Medicin Chem       Date:  2014-08-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.